Efficacy of a combination of esafoxolaner, eprinomectin and praziquantel (NexGard ® Combo) against Thelazia callipaeda in naturally infected cats
Parasite · 2024
DOI: 10.1051/parasite/2024008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Parasite, 2024. Verfasst von Angela Di Cesare und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Medicine, University of Teramo, Località Piano d'Accio, 64100 Teramo, Italy. Hauptthemen laut MEDLINE: Praziquantel, Thelazioidea, Isoxazoles, Naphthalenes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim France.
Abstract (Originalsprache)
This clinical study assessed the efficacy of a topical combination of esafoxolaner, eprinomectin and praziquantel (NexGard ® Combo) in treating cats naturally infected with the eyeworm Thelazia callipaeda (Nematoda, Thelaziidae). On Study Day (SD) 0, sixteen client-owned cats with eyeworm infection were allocated to an untreated control group (G1, 8 cats) or to a NexGard ® Combo treated group (G2, 8 cats) and subjected to ocular examination. Cats in G2 received the treatment as per label recommendations. On SD 7 and 14 (±1), cats were examined for the presence of eyeworms and clinical signs. On SD 14, eyeworms were collected and counted. On SD 7 and 14, all cats in G1 were still infected with eyeworms, while G2 cats were free from eyeworms on SD 7 and 14, demonstrating 100% efficacy ( p < 0.0001). All collected eyeworms were morphologically and molecularly confirmed to be T. callipaeda . On SD 0, fifteen out of the sixteen cats (7 in G1 and 8 in G2) displayed inflammatory ocular signs. On SD 7, all eight untreated cats and seven treated cats displayed inflammatory ocular signs. On SD 14, five out of eight G2 treated cats had recovered, while the eight untreated cats still displayed inflammatory ocular signs. The treatment significantly reduced lacrimation and conjunctivitis ( p = 0.0001). No adverse reactions occurred. This clinical study provides evidence that NexGard ® Combo is highly safe and effective for the treatment of T. callipaeda infection in cats under field conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Medicine, University of Teramo, Località Piano d'Accio, 64100 Teramo, Italy.
- Department of Veterinary Sciences, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, Turin, Italy.
- Boehringer Ingelheim Animal Health, 29 Avenue Tony Garnier, 69007 Lyon, France.
Förderung
- Boehringer Ingelheim France
Zitieren
APA
Di Cesare, A., Zanet, S., Traversa, D., Colombo, M., Tielemans, E., Beugnet, F., & Ferroglio, E. (2024). Efficacy of a combination of esafoxolaner, eprinomectin and praziquantel (NexGard ® Combo) against Thelazia callipaeda in naturally infected cats. Parasite. https://doi.org/10.1051/parasite/2024008
Vancouver
Di Cesare A, Zanet S, Traversa D, Colombo M, Tielemans E, Beugnet F, et al. Efficacy of a combination of esafoxolaner, eprinomectin and praziquantel (NexGard ® Combo) against Thelazia callipaeda in naturally infected cats. Parasite. 2024. doi:10.1051/parasite/2024008
BibTeX
@article{DiCesare2024,
author = {Di Cesare, Angela and Zanet, Stefania and Traversa, Donato and Colombo, Mariasole and Tielemans, Eric and Beugnet, Frederic and Ferroglio, Ezio},
title = {Efficacy of a combination of esafoxolaner, eprinomectin and praziquantel (NexGard ® Combo) against Thelazia callipaeda in naturally infected cats},
journal = {Parasite},
year = {2024},
doi = {10.1051/parasite/2024008}
}
EUVIMED